Ipsen Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ipsen

09.07.13		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.02.13		Eziclen® / Izinova® a New Product for Bowel Cleansing Successfully Completed European Decentralised Registration Procedure (Businesswire)
17.01.13		Teijin Pharma to Launch Ipsen's Somatuline® Subcutaneous Injection in the Treatment of Acromegaly and Pituitary Gigantism in Japan (Businesswire)
07.01.13		Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
07.01.13		Ipsen S.A. : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.01.13		Ipsen's Corporate Agenda for 2013 (Businesswire)
18.12.12		Oncodesign And the Laboratory for Neurobiology and Gene Therapy at The KU Leuven Enter into a Research Collaboration for Advancing Drug Discovery Efforts with Ipsen in Parkinson's Disease (Businesswire)
10.12.12		Active Biotech and Ipsen Announce Completion of Recruitment of Tasquinimod Clinical Phase III Study in Prostate Cancer (Businesswire)
06.12.12		IPSEN S.A.: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
03.12.12		Ipsen and Galderma increase their collaboration for Dysport® in new territories (Businesswire)
20.11.12		Ipsen and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation from FDA for Acquired Hemophilia A (Businesswire)
09.11.12		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
19.10.12		Ipsen to initiate a proof-of-concept study with tasquinimod in additional cancer indications (Businesswire)
03.05.12		Ipsen's First Quarter 2012 Sales (Businesswire)
03.05.11		Ipsen’s first quarter 2011 sales (Businesswire)
03.05.11		Ipsen’s first quarter 2011 sales (Businesswire)
02.03.11		Ipsen’s 2010 results and 2011 sales objectives (Businesswire)
31.08.10		Ipsen’s Half-year 2010 Results (Businesswire)
29.04.10		Ipsen’s Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in a Key Phase III Clinical Trial (Businesswire)
27.04.10		Ipsen and Invida Enter into a Partnership for the Commercialization of Ipsen’s Specialty Care Drugs in South-East Asia (Businesswire)
30.03.10		Dicerna Pharmaceuticals and Ipsen Enter into an Exclusive Research Collaboration for the Development of New Therapeutic Agents in Endocrinology and Oncology (Businesswire)
01.03.10		Ipsen’s 2009 Results and Objectives (Businesswire)
13.11.09		Ipsen’s Decapeptyl® 6-Month Formulation Receives Marketing Authorization in France for the Treatment of Locally Advanced or Metastatic Prostate Cancer (Businesswire)
29.10.09		Ipsen’s Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in the First Phase III Clinical Trial (Businesswire)
29.10.09		Ipsen’s First Nine Months of 2009 Sales and Update of Group Financial Objectives (Businesswire)
20.10.09		Ipsen Grants Menarini Exclusive European Licence Rights to Adenuric® (Febuxostat), Its Novel Treatment for Chronic Hyperuricaemia in Gout (Businesswire)
08.10.09		Ipsen and Spirogen Redesign Their Collaboration for the Development of SJG-136 (Now SG2000) (Businesswire)
15.09.09		Ipsen: Encouraging Preliminary New Data Available for the Treatment of Short Stature Children with Low IGF-1 Levels (Businesswire)
28.08.09		CORRECTING AND REPLACING: Ipsen’s Half Year 2009 Results (Businesswire)
28.08.09		Ipsen’s Half Year 2009 Results (Businesswire)
26.06.09		Ipsen: AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines (Businesswire)
30.04.09		Ipsen and Medicis: FDA Approves DysportTM for Therapeutic and Aesthetic Uses (Businesswire)
12.03.09		Ipsen: AZZALURE® Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines (Businesswire)
02.03.09		Ipsen’s Full Year 2008 Results (Businesswire)
19.01.09		Ipsen: "Creating the Future: New Challenges in Biology and Medicine” (Businesswire)
08.01.09		Ipsen Provides Update on R&D Pipeline and Business Opportunities at Its Investor Day (Businesswire)
29.12.08		FDA Issues Complete Response Letter to Ipsen for Dysport® Biologics License Application (Businesswire)
12.12.08		Ipsen: AFEP / MEDEF Recommendations on Compensation of Executive Directors (Businesswire)
30.09.08		Ipsen: FDA's First-Cycle Review of Dysport(R) to Be Completed by Year-End (Businesswire)
29.08.08		Ipsen's Half Year 2008 Results and Update on Standalone Financial Objectives for the Full Year 2008 (Businesswire)
31.07.08		Ipsen's First Half 2008 Sales, Outlook for the Full Year 2008 and R&D Pipeline Update (Businesswire)
19.05.08		Ipsen and Medicis Announce Acceptance of Reloxin(R) BLA in Aesthetics by FDA (Businesswire)
12.05.08		Tercica Reports First Quarter 2008 Financial Results (Businesswire)
01.05.08		Tercica to Hold 2008 First Quarter Financial Results Conference Call May 12 (Businesswire)
27.02.08		Tercica Reports Fourth Quarter and Year-End 2007 Financial Results (Businesswire)
27.02.08		Ipsen's Full Year 2007 Results and Financial Objectives for the Full Year 2008 (Businesswire)
21.02.08		EMEA Recommends Marketing Authorisation of Ipsen's Adenuric(R) (Febuxostat) for the Treatment of Chronic Hyperuricaemia in Gout (Businesswire)
22.01.08		Tercica Initiates Phase II Clinical Trial with Next-Generation Growth Hormone Product for the Treatment of Short Stature (Businesswire)
11.01.08		Ipsen: Ipsen and The Salk Institute Enter into Strategic Research Agreement (Businesswire)
04.01.08		Ipsen S.A.: Disclosure of Trading in Own Shares (Businesswire)

Erste Seite Zurück | ... | 7 | 8 | 9 | 10 | Weiter

Newssuche

Meistgelesene Nachrichten

Ripple Kurs Prognose: 10 US-Dollar bereits in wenigen Wochen?

NVIDIA vor Zahlen: Bank of America sieht Mega-Potenzial

Bitcoin & Co.: "Dr. Doom" Roubini prognostiziert Krypto-Blase und warnt Anleger

US-Zölle im Fokus: US-Börsen schließen schwach -- ATX schließt tiefer -- DAX letztlich in Rot -- Märkte in Fernost gehen tiefer aus dem Handel

Mercedes-Benz-Aktie fällt: Gewinneinbruch und niedrigere Dividende

Ceres Power-Aktie mit heftigem Kursrutsch: Bosch kündigt Partnerschaft auf

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.02.2025 20:52
Kaufwert:	EUR
	Hinzufügen Speichern